Description
Montaro (Tirzepatide) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist a once-weekly subcutaneous injectable twincretin that simultaneously activates the GIP receptor (GIPR) with potency comparable to native GIP and the GLP-1 receptor (GLP-1R) to potentiate glucose-dependent insulin secretion from pancreatic beta cells, suppress inappropriate glucagon release from pancreatic alpha cells, slow gastric emptying to attenuate postprandial glucose excursions, and engage central satiety circuits in the hypothalamus, producing clinically meaningful reductions in both HbA1c and body weight that exceed those of any previously approved incretin-based agent supplied as a subcutaneous injection in a pre-filled syringe, 1 pre-filled syringe per box, available in strengths of 2.5 mg, 5 mg, and 7.5 mg, and manufactured by Square Pharmaceuticals PLC, Bangladesh.
Its active ingredient, tirzepatide INN, is a 39-amino acid acylated peptide with structural homology to native GIP, engineered to bind and activate both GIPR and GLP-1R within a single molecular entity the first approved dual incretin receptor agonist (twincretin) in the antidiabetic drug class structurally and mechanistically distinct from monoagonist GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide) that activate only the GLP-1 receptor. The co-activation of GIPR by tirzepatide augments the GLP-1R-mediated glycaemic and weight effects by engaging adipose tissue GIP receptors involved in lipid partitioning and by potentiating pancreatic beta cell responsiveness through synergistic cyclic adenosine monophosphate (cAMP) signalling from both receptor pathways simultaneously. In the pivotal SURPASS-1 monotherapy trial (478 patients, 40 weeks), tirzepatide 5 mg achieved a mean HbA1c reduction of 1.87% and tirzepatide 7.5 mg achieved 1.89% from baseline versus 0.04% with placebo, with 87.4% and 91.7% of patients respectively achieving HbA1c below 7.0% versus 19.9% with placebo without hypoglycaemia as monotherapy.
In the SURPASS-2 head-to-head trial versus semaglutide 1 mg (1,879 patients, 40 weeks), tirzepatide demonstrated superior HbA1c reduction (−2.46% vs −1.86%) and superior body weight reduction (−15.7 kg vs −5.5 kg at the highest dose versus semaglutide 1 mg) establishing tirzepatide as the most efficacious approved injectable antidiabetic agent studied against an active comparator in a prospective randomised trial. Searching for Montaro Tirzepatide? Mediaid Pharmacy lists this product across its diabetes medicines and Tirzepatide Medicines portfolios and ships it worldwide.
Basic Product Information of Montaro (Tirzepatide)
| Brand Name | Montaro (Tirzepatide) |
| Product Name | Montaro |
| Generic Name | Tirzepatide INN |
| Drug Class | Dual GIP/GLP-1 Receptor Agonist; Twincretin; Glucose-Dependent Insulinotropic Polypeptide (GIP) Receptor Agonist; Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist; Dual Incretin Receptor Agonist; Once-Weekly Subcutaneous Injectable Antidiabetic Agent; Incretin Mimetic; Glucose-Dependent Insulin Secretion Potentiator; Glucagon Suppressor; Cardiometabolic Agent; Antiobesity Agent (Adjunct in T2DM) |
| Formulation | Subcutaneous Injection (Pre-filled Syringe) |
| Available Strengths | 2.5 mg, 5 mg, and 7.5 mg tirzepatide per pre-filled syringe |
| Available Pack Size | 1 pre-filled syringe per box |
| Recommended Dose & Administration | Initiation dose: 2.5 mg subcutaneously once weekly for 4 weeks. This is a tolerability initiation dose, not the therapeutic maintenance dose it minimises nausea and gastrointestinal adverse effects during treatment commencement. Step 1 (therapeutic): Increase to 5 mg subcutaneously once weekly after completing 4 weeks at 2.5 mg. Step 2: If additional glycaemic control is required after at least 4 weeks at 5 mg, increase to 7.5 mg subcutaneously once weekly the maximum strength available in Montaro pre-filled syringes. Injection sites: Administer subcutaneously into the abdomen (at least 5 cm from the navel), thigh, or upper arm; rotate injection sites with each weekly dose to reduce local injection site reactions. Montaro may be injected at any time of day, with or without food. Missed dose: If a dose is missed and the next scheduled dose is more than 4 days away, administer the missed dose as soon as possible and resume the regular weekly schedule. If the next scheduled dose is 4 days or fewer away, skip the missed dose and continue with the next scheduled weekly injection. Do not administer two doses within 3 days of each other. Renal and hepatic impairment: No dose adjustment is required for mild to moderate renal impairment (eGFR ≥30 mL/min/1.73 m²); use with caution in severe renal impairment. No dose adjustment required for hepatic impairment. Always confirm the dose, injection technique, and escalation schedule with the prescribing endocrinologist before initiating or adjusting Montaro therapy. |
| Primary Indications | Type 2 Diabetes Mellitus (T2DM): As an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus, used as monotherapy or in combination with other antidiabetic agents (metformin, sulfonylurea, SGLT2 inhibitor) or basal insulin when existing therapy does not achieve adequate glycaemic control. Tirzepatide is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. Each treatment decision must account for baseline HbA1c, body weight goals, cardiovascular risk, concomitant antidiabetic medications, renal function, and gastrointestinal tolerability always consult the full prescribing information and the treating endocrinologist or diabetologist before initiating or adjusting therapy. |
| Manufacturer | Square Pharmaceuticals PLC, Bangladesh |
| Country of Origin | Bangladesh |
| Registration | Bangladesh |
| Originator Reference Brand | Mounjaro® (tirzepatide injection, developed and marketed by Eli Lilly and Company approved by the U.S. Food and Drug Administration on May 13, 2022, as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus). Mounjaro® contains tirzepatide INN as the active pharmaceutical ingredient in the same dual GIP/GLP-1 receptor agonist (twincretin) drug class. Montaro is manufactured by Square Pharmaceuticals PLC in Bangladesh and is supplied through Mediaid Pharmacy for international procurement. |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Storage Conditions | Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze; discard Montaro pre-filled syringes that have been frozen. If necessary, each pre-filled syringe may be stored unrefrigerated at room temperature up to 30°C (86°F) for a maximum of 21 days. Protect from light and direct heat. Keep in the original packaging until use. Keep out of the reach of children. Do not use after the expiry date printed on the carton and pre-filled syringe label. |
How Montaro (Tirzepatide) Works: Dual GIP and GLP-1 Receptor Agonism and Twincretin Pharmacology in Type 2 Diabetes
Tirzepatide INN is a 39-amino acid acylated peptide that functions as a dual agonist at two distinct incretin hormone receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). This dual receptor mechanism the first of its kind among approved antidiabetic agents, earning tirzepatide the designation “twincretin” simultaneously activates two complementary glucose-lowering and weight-reducing signalling pathways that monoagonist GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide) cannot replicate. GLP-1 is secreted by intestinal L cells in the distal ileum and colon following nutrient ingestion, stimulating glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon secretion from pancreatic alpha cells, slowing gastric emptying to reduce postprandial glucose excursions, and activating hypothalamic and brainstem satiety circuits.
GIP is secreted by K cells in the duodenum and proximal jejunum in response to fat and carbohydrate ingestion, potentiating glucose-dependent insulin secretion through a distinct cAMP signalling cascade in pancreatic beta cells and engaging adipose tissue GIPR-expressing cells involved in lipid partitioning and energy balance. In type 2 diabetes mellitus, both incretin axes are functionally impaired: the GLP-1 response is markedly attenuated and the residual GIP response fails to elicit a normal insulin secretory response in the insulin-resistant beta cell precisely the dual incretin deficit that tirzepatide’s co-receptor engagement addresses by simultaneously reconstituting both GIP and GLP-1 signalling arms within a single molecular entity.
The structural basis of tirzepatide’s dual receptor activity lies in its peptide architecture: a 39-amino acid sequence with structural homology to native GIP at the N-terminus, optimised through amino acid substitutions for balanced GIPR and GLP-1R binding affinity, conjugated at lysine-26 to a C20 fatty diacid moiety via a gamma-glutamic acid-miniPEG linker a modification that confers high albumin binding exceeding 99%, protects the peptide from N-terminal DPP-4 cleavage that inactivates native GIP and GLP-1 within 1 to 2 minutes of portal entry, and provides an extended elimination half-life of approximately 5 days that supports once-weekly subcutaneous dosing.
Tirzepatide activates GIPR with potency approximately equivalent to native GIP and activates GLP-1R with approximately 5-fold lower potency than native GLP-1 yet produces GLP-1R-mediated pharmacological effects (insulin secretion, glucagon suppression, gastric emptying delay, appetite suppression, body weight reduction) that equal or exceed those of optimised GLP-1 monoagonists in head-to-head clinical trials, driven by receptor co-stimulation synergy, adipose tissue GIPR contributions to energy balance, and tissue-level interactions between the two simultaneously activated signalling pathways.
Pharmacokinetically, following subcutaneous administration, tirzepatide reaches peak plasma concentration (Tmax) at approximately 8 to 72 hours, achieves steady-state concentrations by 4 weeks of once-weekly dosing, and is eliminated primarily via proteolytic degradation of the peptide backbone and fatty acid beta-oxidation with no single dominant cytochrome P450 (CYP) metabolic pathway and no clinically relevant accumulation with weekly dosing in patients across a broad range of renal and hepatic function. The combined pharmacological outcome of dual GIPR/GLP-1R agonism augmented glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and superior appetite suppression compared to GLP-1 monoagonism produces the superior HbA1c and body weight reductions observed across the SURPASS clinical trial programme. For the complete range of diabetes medicines at Mediaid Pharmacy, browse the full portfolio for worldwide shipping.
Montaro (Tirzepatide): Indications, Dosing, and Key Safety Information
| Approved Indications | Type 2 Diabetes Mellitus (T2DM): Adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. Montaro (Tirzepatide) is used as monotherapy when other oral agents are not tolerated or are contraindicated, and as add-on combination therapy with metformin, sulfonylureas, SGLT2 inhibitors, or basal insulin when single-agent or existing combination therapy fails to achieve adequate HbA1c targets. Tirzepatide is not indicated for type 1 diabetes mellitus or diabetic ketoacidosis. The treating endocrinologist determines appropriate candidacy, dose titration schedule, and combination regimen based on individual patient HbA1c targets, weight goals, cardiovascular risk, renal function, and gastrointestinal tolerability profile. |
| Dosing Schedule | Week 1–4 (Initiation): 2.5 mg subcutaneously once weekly tolerability initiation dose, not a therapeutic maintenance dose. Week 5 onwards (Step 1): 5 mg subcutaneously once weekly. After ≥4 weeks at 5 mg (Step 2, if needed): 7.5 mg subcutaneously once weekly the maximum strength available in Montaro pre-filled syringes. Inject subcutaneously into abdomen, thigh, or upper arm; rotate injection sites each week. Administer at any time of day, with or without meals. |
| Common Adverse Reactions | The most commonly reported adverse reactions with tirzepatide in the SURPASS Phase 3 clinical trial programme are gastrointestinal: nausea (12–18% at 5 mg, 17–24% at higher doses), diarrhoea (12–17%), vomiting (5–11%), and constipation (6–11%), predominantly occurring during dose initiation and escalation phases and generally transient. The 2.5 mg initiation dose protocol is specifically designed to reduce the frequency and severity of these gastrointestinal effects during the first 4 weeks of treatment. Injection site reactions (erythema, pain, bruising) are reported in approximately 3–7% of patients. Hypoglycaemia does not occur with Montaro as monotherapy due to its strictly glucose-dependent insulin secretion mechanism; hypoglycaemia risk increases when tirzepatide is combined with a sulfonylurea or basal insulin, and dose reduction of the sulfonylurea or insulin should be considered. Rare serious adverse reactions include acute pancreatitis (discontinue Montaro immediately if suspected), severe hypersensitivity reactions including anaphylaxis and angioedema, and acute gallbladder disease (cholelithiasis, cholecystitis). Montaro (Tirzepatide) carries a boxed warning for thyroid C-cell tumours based on rodent carcinogenicity data it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Always discuss the complete safety profile with the treating endocrinologist before initiating or continuing Montaro therapy. |
| Drug Interactions | Oral medications requiring rapid absorption or with narrow therapeutic index: Tirzepatide delays gastric emptying and may reduce the peak plasma concentration (Cmax) and alter the time to peak concentration (Tmax) of concomitantly administered oral medications. Particular caution is warranted with narrow therapeutic index oral drugs (e.g., warfarin, cyclosporine, digoxin). Oral contraceptives: When initiating Montaro or escalating the dose, gastric emptying delay may transiently reduce peak concentrations of oral contraceptives switch to non-oral contraception or add a barrier method for 4 weeks after starting Montaro and for 4 weeks after each dose escalation step. Warfarin (and other vitamin K antagonists): Monitor INR more frequently when initiating or dose-escalating Montaro due to the potential effect on warfarin absorption kinetics. Insulin secretagogues and basal insulin: Concomitant use with a sulfonylurea (glimepiride, glibenclamide) or basal insulin (insulin glargine, insulin detemir) increases hypoglycaemia risk consider reducing the sulfonylurea or insulin dose when adding Montaro to existing antidiabetic therapy. Other GLP-1 receptor agonists: Do not combine Montaro (Tirzepatide) with another GLP-1 receptor agonist (semaglutide, liraglutide, dulaglutide, exenatide) as additive receptor agonism provides no established additional glycaemic benefit and compounds gastrointestinal adverse effects. |
| Contraindications | Montaro (Tirzepatide) is contraindicated in: patients with a personal or family history of medullary thyroid carcinoma (MTC); patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); patients with known serious hypersensitivity to tirzepatide or any component of the Montaro formulation (including anaphylaxis or angioedema). Tirzepatide is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. |
| Renal Impairment | No dose adjustment of Montaro (Tirzepatide) is required for mild to moderate renal impairment (eGFR ≥30 mL/min/1.73 m²). Use with caution in severe renal impairment (eGFR <30 mL/min/1.73 m²) due to limited clinical data; the predominantly non-renal elimination of tirzepatide means pharmacokinetic exposure is not substantially increased by renal impairment, but gastrointestinal adverse effects (nausea, vomiting, diarrhoea) may precipitate dehydration and acute kidney injury in renally vulnerable patients necessitating closer clinical monitoring, hydration counselling, and renal function assessment during dose initiation and escalation. Consult the treating endocrinologist and nephrologist for individualised guidance in patients with advanced chronic kidney disease. |
| Pregnancy & Lactation | Montaro (Tirzepatide) is not recommended during pregnancy. Tirzepatide caused adverse embryo-fetal developmental effects in animal reproductive toxicity studies at clinically relevant exposures; adequate and well-controlled human data in pregnancy are not available. The risks of uncontrolled maternal hyperglycaemia during pregnancy and of tirzepatide fetal exposure must be carefully weighed insulin remains the preferred antidiabetic agent during pregnancy for type 2 diabetes mellitus. Women of childbearing potential should use effective contraception throughout Montaro therapy; if pregnancy occurs or is planned, discontinue Montaro and transition to insulin therapy immediately under endocrinologist guidance. Breastfeeding is not recommended during Montaro treatment, as it is unknown whether tirzepatide is excreted in human breast milk; the risk to the nursing infant cannot be excluded. |
Who Should Use Montaro (Tirzepatide)?
Montaro (Tirzepatide) is indicated for adults with type 2 diabetes mellitus requiring improved glycaemic control as an adjunct to diet and exercise a patient population defined by progressive insulin secretory failure, marked GLP-1 and GIP response impairment, postprandial glucagon excess, and frequently co-occurring excess body weight, for whom a once-weekly dual incretin receptor agonist provides simultaneous glycaemic and cardiometabolic benefits mechanistically unachievable by existing oral antidiabetic classes or monoagonist injectable agents.
First, adults with type 2 diabetes requiring substantial HbA1c reduction those presenting with baseline HbA1c above 8.5% or requiring reductions exceeding 1.5% to achieve target represent the primary population where tirzepatide’s superior efficacy profile is most clinically relevant. In SURPASS-1 monotherapy (40 weeks, 478 patients), tirzepatide 5 mg achieved 1.87% HbA1c reduction with 87.4% of patients reaching HbA1c below 7.0%, and 7.5 mg achieved 1.89% reduction with 91.7% achieving the target versus 0.04% reduction and 19.9% target achievement with placebo, demonstrating the magnitude of glycaemic correction tirzepatide provides as monotherapy at the initiation and early escalation doses available in Montaro pre-filled syringes.
Second, adults with type 2 diabetes and significant overweight or obesity for whom concurrent meaningful weight loss is a clinical priority alongside glycaemic control represent an especially important population for Montaro therapy. In SURPASS-2 versus semaglutide 1 mg (40 weeks), tirzepatide 5 mg produced mean body weight reduction of 7.6 kg and 7.5 mg produced 9.5 kg reductions that translate to clinically meaningful improvements in adiposity, blood pressure, and cardiovascular risk markers independent of HbA1c lowering, and that significantly exceeded semaglutide 1 mg (5.7 kg) at both doses.
Third, adults with type 2 diabetes requiring injectable antidiabetic therapy escalation beyond oral agents, or those in whom GLP-1 monoagonist therapy has produced suboptimal glycaemic or weight outcomes, benefit from tirzepatide’s additional GIPR co-agonism a mechanistically distinct pathway not activated by semaglutide, liraglutide, or dulaglutide and from the once-weekly subcutaneous injection schedule that eliminates the daily injection burden of short-acting agents.
Fourth, adults with type 2 diabetes for whom minimising hypoglycaemia risk is a clinical priority benefit from tirzepatide’s glucose-dependent, insulin-only-when-needed mechanism, which produced no hypoglycaemia as monotherapy across SURPASS-1 and SURPASS-2. Endocrinology centres and diabetes specialist clinics co-sourcing Montaro alongside other specialty diabetes medicines can browse the Mediaid Pharmacy diabetes medicines portfolio for the full selection available for international delivery.
Global Supplier: Mediaid Pharmacy Worldwide Shipping for Montaro (Tirzepatide)
Mediaid Pharmacy is a Dhaka-based supplier of specialty diabetes, endocrinology, and metabolic medicines with worldwide shipping to patients, diabetes specialist centres, endocrinology clinics, hospital pharmacy departments, and international distributors across all regions. Montaro (Tirzepatide), manufactured by Square Pharmaceuticals PLC in Bangladesh, is supplied as a subcutaneous injection in pre-filled syringes available in 2.5 mg, 5 mg, and 7.5 mg strengths, 1 pre-filled syringe per box with pricing quotations, stock confirmation, full product documentation, and end-to-end international delivery tracking for every order.
The pre-filled syringe formulation of Montaro supports once-weekly self-administration without requiring dose measurement, device assembly, or needle attachment beyond the pre-filled unit, making procurement, dispensing, patient instruction, and injection technique training straightforward for diabetes clinics and endocrinology programmes co-sourcing injectable antidiabetic therapy across diverse patient populations. Diabetes specialist centres managing type 2 diabetes requiring superior glycaemic and weight-reduction efficacy, endocrinology programmes requiring a dual GIP/GLP-1 receptor agonist with the SURPASS Phase 3 clinical evidence base, hospital pharmacy departments co-sourcing injectable antidiabetic agents for inpatient or outpatient use, international distributors, and individual patients can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all inquiries regarding Montaro Tirzepatide stock availability, current pricing, and international delivery timelines to their country.
Procurement teams co-sourcing Montaro with other specialty diabetes or metabolic medicines can browse the complete Mediaid Pharmacy diabetes medicines collection and the Square Pharmaceuticals medicines portfolio before requesting a consolidated quotation.
Why Choose Montaro (Tirzepatide) from Mediaid Pharmacy?
Montaro (Tirzepatide) delivers the most clinically documented HbA1c reduction and body weight reduction among approved injectable antidiabetic agents a differentiation established in the SURPASS clinical trial programme through a unique twincretin mechanism of simultaneous GIP and GLP-1 receptor co-activation that no single-receptor GLP-1 agonist, DPP-4 inhibitor, SGLT2 inhibitor, or insulin class member can replicate in a single weekly injection. In SURPASS-2 (1,879 adults with type 2 diabetes, 40 weeks), tirzepatide at higher doses produced mean HbA1c reduction of 2.46% versus 1.86% with semaglutide 1 mg and mean body weight reduction of 15.7 kg versus 5.5 kg with semaglutide demonstrating statistically significant superiority (p<0.001 for both endpoints) over the most widely prescribed GLP-1 receptor agonist in a prospective, randomised, active-controlled head-to-head trial; this clinical evidence of superiority over semaglutide represents an Information Gain advantage for endocrinology programmes evaluating injectable antidiabetic intensification options.
From a tolerability architecture perspective, the mandatory 2.5 mg initiation dose embedded in Montaro’s approved dosing schedule a 4-week tolerability titration before advancing to the 5 mg therapeutic dose reduces gastrointestinal adverse event-related treatment discontinuation compared to initiating directly at therapeutic doses, supporting sustained patient adherence through the dose escalation period.
The absence of hypoglycaemia as monotherapy a direct consequence of tirzepatide’s strictly glucose-dependent insulin secretion mechanism, which automatically extinguishes the insulin secretory signal as plasma glucose normalises means Montaro can be initiated without hypoglycaemia dietary restriction protocols or blood glucose monitoring schedules beyond standard diabetic care, clinically differentiating it from sulfonylureas and insulin as a glycaemic intensification agent.
From a dosing convenience standpoint, the once-weekly subcutaneous injection schedule eliminates the daily injection burden of liraglutide and the daily oral medication adherence requirement of DPP-4 inhibitors and SGLT2 inhibitors, supporting high adherence profiles in working-age patients, elderly patients, and all populations who benefit from weekly rather than daily medication routines.
Montaro, manufactured by Square Pharmaceuticals PLC in Bangladesh, delivers the same active pharmaceutical ingredient tirzepatide INN in pre-filled syringes at the approved subcutaneous injection formulation, sourced through Mediaid Pharmacy with worldwide shipping to patients and healthcare providers globally. To source additional Square Pharmaceuticals medicines and the full range of tirzepatide medicines available at Mediaid Pharmacy, browse both portfolios and contact the team for a personalised quotation.
Frequently Asked Questions About Montaro (Tirzepatide)
What is Montaro (Tirzepatide) used for?
Montaro (Tirzepatide) is a dual GIP and GLP-1 receptor agonist a twincretin used as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. Administered once weekly as a subcutaneous injection, Montaro is used as monotherapy when metformin or other oral agents are not tolerated or are contraindicated, and as add-on combination therapy with metformin, sulfonylureas, SGLT2 inhibitors, or basal insulin when existing treatment fails to achieve adequate HbA1c control. Montaro (Tirzepatide) works by simultaneously activating the GIP receptor (GIPR) and the GLP-1 receptor (GLP-1R) stimulating glucose-dependent insulin secretion from pancreatic beta cells, suppressing inappropriate glucagon release, slowing gastric emptying to reduce postprandial glucose excursions, and engaging central satiety pathways to reduce appetite and body weight producing clinically superior HbA1c and body weight reductions compared to monoagonist GLP-1 receptor agonists in head-to-head prospective trials. The originator brand for tirzepatide is Mounjaro® (Eli Lilly and Company, FDA-approved May 13, 2022 for adults with T2DM). Montaro, manufactured by Square Pharmaceuticals PLC in Bangladesh, is available through Mediaid Pharmacy with worldwide shipping to patients, diabetes specialist centres, and endocrinology clinics globally.
What is the generic name of Montaro?
The generic name of Montaro is tirzepatide INN. Montaro is the brand name registered by Square Pharmaceuticals PLC for tirzepatide manufactured in Bangladesh. Montaro is formulated as a subcutaneous injection in pre-filled syringes, available in 2.5 mg, 5 mg, and 7.5 mg strengths, supplied as 1 pre-filled syringe per box supporting the approved once-weekly dosing schedule from initiation at 2.5 mg through stepwise dose escalation as directed by the treating endocrinologist. The originator reference brand is Mounjaro® (Eli Lilly and Company). Mediaid Pharmacy distributes Montaro globally with worldwide shipping to patients, diabetes centres, endocrinology clinics, and hospital pharmacy departments.
What is the difference between Montaro (Tirzepatide) and Mounjaro® (Tirzepatide)?
Montaro and Mounjaro® both contain tirzepatide INN as the active pharmaceutical ingredient and share the same dual GIP/GLP-1 receptor agonist (twincretin) mechanism of action for type 2 diabetes mellitus. Mounjaro® is the originator brand developed and marketed by Eli Lilly and Company, approved by the FDA on May 13, 2022, as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. Montaro is manufactured by Square Pharmaceuticals PLC in Bangladesh and is supplied in pre-filled syringes in 2.5 mg, 5 mg, and 7.5 mg strengths the initiation and early titration doses corresponding to the first 8+ weeks of the approved tirzepatide dosing schedule with 1 pre-filled syringe per box, available through Mediaid Pharmacy for international procurement by specialist diabetes centres and patients in regions where Mounjaro® may be unavailable or cost-prohibitive. For the full range of tirzepatide medicines at Mediaid Pharmacy, browse the complete collection.
How is Montaro (Tirzepatide) administered?
Montaro (Tirzepatide) is administered once weekly as a subcutaneous injection using the pre-filled syringe. Recommended injection sites are the abdomen (at least 5 cm from the navel), the thigh, or the upper arm rotate injection sites with each weekly administration to minimise local injection site reactions such as erythema, bruising, and pain. Montaro may be administered at any time of day, independently of meals. The approved initiation schedule begins with 2.5 mg once weekly for 4 weeks; after 4 weeks, advance to 5 mg once weekly. If additional glycaemic control is needed after at least 4 weeks at 5 mg, increase to 7.5 mg once weekly. If a dose is missed and the next scheduled dose is more than 4 days away, administer the missed dose as soon as possible and resume the regular weekly schedule. If the next scheduled dose is 4 days or fewer away, skip the missed dose and continue with the next scheduled weekly injection never administer two doses within 3 days of each other. Store Montaro pre-filled syringes refrigerated at 2°C to 8°C until use. Always confirm injection technique and dose escalation timing with the prescribing endocrinologist before commencing Montaro therapy.
What are the side effects of Montaro (Tirzepatide)?
The most common side effects of Montaro (Tirzepatide) are gastrointestinal: nausea (reported in 12–18% of patients at 5 mg), diarrhoea (12–17%), vomiting (5–11%), and constipation (6–11%) predominantly occurring during dose initiation and escalation and typically transient. The mandatory 2.5 mg initiation dose protocol for the first 4 weeks is specifically designed to reduce the frequency and severity of gastrointestinal adverse effects during treatment commencement. Injection site reactions (erythema, bruising, pain at the injection site) are reported in approximately 3–7% of patients; rotating injection sites each week reduces their incidence. Hypoglycaemia does not occur with Montaro as monotherapy due to its glucose-dependent insulin secretion mechanism; hypoglycaemia risk increases when Montaro is combined with a sulfonylurea or basal insulin, and dose reduction of those agents should be considered. Rare but serious adverse reactions include acute pancreatitis discontinue Montaro immediately if pancreatitis is suspected and severe hypersensitivity reactions including anaphylaxis and angioedema. Montaro carries a boxed warning for thyroid C-cell tumours (medullary thyroid carcinoma observed in rodent studies at clinically relevant exposures); instruct patients to report any neck masses, hoarseness, dysphagia, or persistent dysphonia. Always discuss the full safety profile, thyroid carcinoma family history, contraindications, and combination therapy hypoglycaemia risk with the treating endocrinologist before and throughout Montaro treatment.
Does Montaro (Tirzepatide) cause weight loss?
Yes. Montaro (Tirzepatide) produces clinically meaningful and dose-dependent body weight reductions in adults with type 2 diabetes, driven by its dual GIP and GLP-1 receptor agonism acting on hypothalamic satiety circuits to reduce appetite, gastric emptying delay reducing caloric absorption rate, and adipose tissue GIPR engagement modulating energy partitioning. In SURPASS-1 monotherapy (40 weeks), tirzepatide 5 mg produced mean body weight reduction of 7.0 kg and 7.5 mg produced 7.8 kg versus 0.7 kg with placebo without dietary intervention beyond standard diet-and-exercise counselling. In SURPASS-2 vs semaglutide 1 mg (40 weeks, 1,879 patients), tirzepatide 5 mg produced mean weight reduction of 7.6 kg and 7.5 mg produced 9.5 kg significantly greater than semaglutide 1 mg (5.7 kg) at both doses (p<0.001). These weight reductions are accompanied by significant improvements in waist circumference, systolic blood pressure, triglycerides, and markers of insulin resistance, supporting tirzepatide’s role as a comprehensive cardiometabolic agent beyond glycaemic control. The treating endocrinologist determines whether Montaro Tirzepatide is the appropriate agent and dose based on the individual patient’s clinical profile, glycaemic targets, and weight-loss goals. For the full range of diabetes medicines at Mediaid Pharmacy available with worldwide shipping, browse the complete portfolio.
How does Tirzepatide (Montaro) compare to semaglutide for type 2 diabetes?
Tirzepatide (Montaro) and semaglutide (originator brand: Ozempic®) are both once-weekly subcutaneous injectable antidiabetic agents, but they act through different receptor mechanisms. Semaglutide is a monoagonist GLP-1 receptor agonist it activates only the GLP-1R. Tirzepatide is a dual GIP/GLP-1 receptor agonist (twincretin) that simultaneously activates both the GIPR and GLP-1R, adding an incretin signalling arm that semaglutide does not engage. In the SURPASS-2 head-to-head trial (1,879 adults with T2DM, 40 weeks), tirzepatide achieved statistically significantly greater reductions in HbA1c and body weight compared to semaglutide 1 mg at all doses studied with tirzepatide 5 mg producing −1.94% HbA1c reduction and 7.6 kg weight loss versus −1.86% and 5.7 kg with semaglutide 1 mg (p<0.001 for non-inferiority; tirzepatide 10 mg and 15 mg also demonstrated superiority). This superiority of tirzepatide over the most widely prescribed GLP-1 receptor agonist in a randomised, active-controlled trial is the defining clinical differentiation of the twincretin class. The full selection of tirzepatide medicines at Mediaid Pharmacy is available for worldwide shipping contact the team for pricing and stock availability.
Can I order Montaro (Tirzepatide) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Square Pharmaceuticals Montaro (Tirzepatide) pre-filled syringes available in 2.5 mg, 5 mg, and 7.5 mg strengths to patients, diabetes specialist centres, endocrinology clinics, hospital pharmacy departments, and healthcare providers globally. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or email info@mediaidpharmacy.com for pricing, current stock availability, and international delivery details for your country.
Order Montaro (Tirzepatide) with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com




Reviews
There are no reviews yet.